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Background: The molecular etiology of thyroid carcinoma (TC) and other thyroid diseases which may present
malignant precursor lesions is not fully explored yet. The purpose of this study was to estimate frequency, type and
clinicopathological value of BRAF exon 15 mutations in different types of cancerous and non-cancerous thyroid
lesions originating in an ethnically diverse population.
Methods: BRAF exon 15 was sequenced in 381 cases of thyroid lesions including Hashimoto´s thyroiditis, nodular
goiters, hyperplastic nodules, follicular adenomas (FA), papillary TC (PTC), follicular variant PTC (FVPTC),
microcarcinomas of PTC (micro PTC; tumor size ≤ 1 cm), follicular TC (FTC), and non-well differentiated TC
(non-WDTC).
Results: We identified BRAF mutations in one of 69 FA, 72 of 115 (63%) PTC, seven of 42 (17%) FVPTC, 10 of 56
(18%) micro PTC, one of 17 (6%) FTC, and one of eight (13%) non-WDTC. Most of the cases showed the common
V600E mutation. One case each of PTC, FVPTC, and FTC harbored a K601E mutation. A novel BRAF mutation was
identified in a FA leading to deletion of threonine at codon 599 (p.T599del). A rare 3-base pair insertion was
detected in a stage III PTC resulting in duplication of threonine at codon 599 (p.T599dup). Patients with PTC
harboring no BRAF mutation (BRAFwt) were on average younger than those with a BRAF mutation (BRAFmut) in the
PTC (36.6 years vs. 43.8 years). Older age (≥ 45 years) in patients with PTC was significantly associated with tumor
size ≥ 4 cm (P = 0.018), vessel invasion (P = 0.004), and distant metastasis (P = 0.001). Lymph node (LN)
involvement in PTC significantly correlated with tumor size (P = 0.044), and vessel invasion (P = 0.013). Of notice,
taken the whole TC group, family history of thyroid disease positively correlated with capsular invasion (P = 0.025).
Conclusions: Older age is manifold associated with unfavorable tumor markers in our series. The K601E identified
in a PTC, FVPTC, and FTC seems to be more distributed among different histological types of TC than previously
thought. The T599del is a yet undescribed mutation and the rare T599dup has not been reported as a mutation in
PTC so far.
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TC represents a considerable cancer burden worldwide [1,2].
In Saudi Arabia it is considered as the fourth most common
cancer type with 6.4% of all diagnosed cancers [3]. Median age
of women diagnosed with TC in Saudi Arabia is considerable
lower than for men (37 years vs. 43 years). Notably, females in
this country are more commonly diagnosed with FVPTC
(19.3% vs. 9.6%) and micro PTC (7.4% vs. 2.6%) than males.
Differentiated types of TC arising from endodermally
derived follicular cells comprise papillary TC (PTC), follicular
TC (FTC), and Hurthle cell carcinoma. Hurthle cell carcin-
omas are also considered as a subtype of FTC. Anaplastic
TC (ATC) is considered as undifferentiated TC which either
may evolve de novo or from PTC or FTC [4]. Medullary TC
(MTC) are derived from calcitonin-producing C cells and
own a different etiology involving commonly mutations in
the RET oncogene. PTC represents about 80% of differen-
tiated TC with an increasing trend while FTC (~11%), Hurthle
cell carcinoma (~3%), MTC (~4%), and ATC (~2%) represent
minor variants [2]. A study on the pattern of TC arising in
Jeddah, an ethnically diverse metropolis in Western Saudi
Arabia, revealed a common distribution of histological types:
PTC (82%), FTC (4.4%), ATC (6.7%), and MTC (6.7%) [5].
The pathogenesis of the majority of TC is affected by som-
atic mutations or rearrangements in known TC genes. The
BRAF gene is the most frequently mutated gene in TC. BRAF
is a cytoplasm receptor serine/threonine kinase and a key
molecule in the mitogen activated protein kinase (MAPK)
pathway. It is mutated in diverse human malignancies al-
though the frequency varies significantly between different
types of cancers [6]. In malignant melanomas and in TC,
which both are oncogenic transformations of neural crest
derived cell lineages, frequency of BRAF mutations can exceed
80% of the cases [6,7]. BRAF activation affects in the vast ma-
jority of cases codon 600 located within the regulatory domain
encoded by exon 15. Most common mutation at codon 600 is
a valine-to-glutamic acid transversion (V600E). This mutation
disrupts the inactive conformation of BRAF as it mimics acti-
vational phosphorylation at the adjacent residues and results
in constitutive downstream signaling [8]. Other BRAF activa-
tion mutations are far less common in TC like the K601E mu-
tation that is commonly restricted to FVPTC [9]. Although
the prognostic impact of BRAF mutations in PTC is contro-
versially discussed, the V600E mutation seems to be a valid
target for molecular therapy as this mutation confers elevated
resistance to iodine ablation [7,10]. We assessed the impact of
BRAF mutations in cancerous and non-cancerous thyroid




We examined 381 cases of thyroid lesions from 376 patients
which were treated surgically in the period between January1995 to June 2011 at the King Abdulaziz University Hospital,
Jeddah, and the King Faisal Specialist Hospital & Research
Center, Jeddah, or were referral/consultant cases from other
regional hospitals. In five cases, tumor and non-tumor
lesions from the same patient were evaluated in the study
separately. Saudi Arabian nationality was reported for 61% of
the patients and 27% originated from other MENA (Middle
East and North Africa) countries. A minority of patients ori-
ginated from other world regions (8%) or patient`s national-
ity was not recorded (4%). Histopathological diagnosis and
staging of thyroid lesions was performed by an oncologic
pathologist (JM) according to established criteria [11,12].
Cases were selected on basis of sample and data availability.
With the exception of MTC [13] the most common, surgi-
cally treated thyroid diseases were included in the study, i.e.
Hashimoto´s thyroiditis, nodular goiters, hyperplastic lesions,
FA, FTC (including Hurthle cell carcinomas), PTC (> 1 cm),
FVPTC (> 1 cm), micro PTC (≤ 1 cm) and non-well differen-
tiated TC (non-WDTC), The non-WDTC group comprised
poorly differentiated insular variant PTC, combinatorial PTC/
ATC, and ATC. PTC (> 1 cm) and FVPTC (> 1 cm) are here-
inafter referred as PTC and FVPTC, respectively.
Demographic and clinicopathological data were compiled
from patients’ files and included age, gender, family history
of thyroid disorders/lesions, histological type, vessel (lymph-
atic, perineural, or vascular) invasion, capsular invasion,
tumor extension, tumor size, multifocal tumors (including
cases of subsequent partial thyroidectomies), lymph node in-
volvement, distant metastasis (comprising radiologic find-
ings), and tumor stage. Information to family history of
thyroid disorders/lesions was voluntarily given by patients
and regarded as positive if at least one first degree relative or
two second degree relatives were affected. This study was
approved by the ethical review boards of both institutions.
Mutational screening
Included in mutational analysis of BRAF exon 15 were speci-
mens from primary thyroid lesions except in 15 cases in
which only specimens from a recurrence or metastasis were
available. A pathologist (JM) has reviewed each case and
chose only specimens with not less than 70% of abnormal or
tumor cells, respectively. Genomic DNA was extracted in
the majority of cases from 10 μm sections of formalin-fixed
and paraffin-embedded (FFPE) material and using conven-
tional xylene/ethanol treatment, overnight incubation with
proteinase K, and subsequent DNA purification utilizing the
QIAmp DNA FFPE tissue kit (Qiagen, Hilden, Germany). In
116 cases native or fresh-frozen (FF) specimens were pre-
served and in these cases the QiAmp DNAmini kit was used
for DNA purification. DNA concentration was measured
with the Nanodrop device (Thermo Scientific, Wilmington,
DE).
The standard PCR protocol was performed as described
earlier [13]. PCR products were checked by electrophoresis
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to cycle sequence reactions using nested primers overlap-
ping with the PCR primers and the BigDye Terminator V3.1
Cycle Sequencing kit (Applied Biosystems, Foster City, CA,
USA). Purified sequencing products were finally resolved by
capillary electrophoresis on an ABI PRISM 3130 Sequencer.
Sequences were screened for BRAF exon 15 mutations
using a combination of manual readout of electrophero-
grams and the online NCBI's BLAST database [14].
Statistical analysis
Associations of demographic data, clinicopathological fac-
tors, and BRAF mutational status (BRAFwt vs. BRAFmut) in
histological types of TC were evaluated using the non-
parametric Wilcoxon rank sum test or Fisher`s exact test for
contingency tables in the 2-sided configuration. P-value for
accepting significance was p = 0.05. Statistical analysis was
performed using the SPSS statistics 16 program (IBM Corp.,
New York, NY).
Results
The hotspot region in BRAF exon 15 was screened for muta-
tions in 381 cases of cancerous and non-cancerous thyroid
lesions. The case series comprised 10 Hashimoto`s thyroidi-
tis lesions, 46 nodular goiters, 18 hyperplastic nodules, 69
FA, 115 PTC, 42 FVPTC, 56 micro PTC (≤ 1 cm), 17 FTC,
and eight non-WDTC (2 insular PTC, 1 PTC/ATC, and 5
ATC) (Table 1). Mean age at diagnosis in non-malignant
lesions ranged between 34.4 years in patients with hyperplas-
tic nodules and 41.9 years in patients with goiter. In the TC
group, mean age varied between 36.4 years in patients with
micro PTC and 59 years in non-WDTC cases. Patients with
micro PTC were on average 4 years younger than their PTC
and FVPTC counterparts. Number of female cases predomi-
nated in all histological types. Of notice, female to male ratio
was considerably higher in micro PTC than in PTC (6:1 vs.
2.3:1). Almost all micro PTC were classified as stage I tumors
except two multifocal stage III tumors (follicular variant inTable 1 Demographic and BRAF mutational survey in thyroid




Thyroiditis 10 36.7 ±12.5 10:0
Goiter 46 41.9 ±11.4 2.3:1
Hyperplastic 18 34.4 ±12.5 8:1
FA 69 38.4 ±13.1 3:1
FTC 17 40.4 ±16.7 3.3:1
PTC 115 41.1 ±15.5 2.3:1
FVPTC 42 40.5 ±15.6 5:1
Micro PTC 56 36.4 ±13.5 6:1
Non-WDTC 8 59.0 ±10.1 7:1
1Wt, BRAF wild type; mut, BRAF mutated.one case) and one stage IV tumor (oncocytic variant)
(Table 2). The majority of cases were stage I tumors in PTC
(64%), FVPTC (57%), and FTC (65%). Seven of eight non-
WDTC cases were stage IV tumors and one was a stage II
tumor. Follow-up period in TC patients ranged between 0
and 23 years (mean, 3.2 years; SD 3.2). Distant metastases
were reported for PTC (15%), FVPTC (17%), FTC (6%), and
non-WDTC (50%). Eight patients deceased from disease
(age at first diagnosis, 49 to 78 years; mean age, 61 years);
tumor progression in these patients was primarily confined
to regional sites in two cases (1 PTC and 1 PTC with tall cell
features metastasized as ATC), to distant sites in four cases
(1 PTC, 1 FTC, 1 PTC/ATC and 1 ATC) and to regional
and distant sites in two cases (1 PTC and 1 FVPTC). The
mean survival period of these patients was 3.9 years (SD 3.4).
Among non-malignant thyroid lesions one of 69 FA exhib-
ited a BRAF mutation. In thyroid malignancies we identified
BRAF mutations in 72 of 115 PTC (63%) seven of 42 (17%)
FVPTC, 10 of 56 (18%) micro PTC, one of 17 (6%) FTC,
and one of eight (13%) non-WDTC (Table 1). Most of the
BRAF mutations were the common point mutation in codon
600 leading to substitution of valine by glutamic acid
(V600E). One PTC, FVPTC, and FTC each harbored a point
mutation in codon 601 resulting in substitution of lysine by
glutamic acid (K601E). The K601E mutation that is usually
associated with FVPTC histology was identified in case of
the FTC (Figure 1A, B) in FF as well as FFPE samples of the
tumor. The K601E mutation in the PTC was detected in the
primary tumor as well as in the regional progressive metasta-
sis (Figure 1C, D). A yet undescribed BRAF mutation was
detected in different sections of a FA (Figure 1E, F). This 3-
base-pair deletion at codon 599 erases threonine 599
(T599del) (Figure 2A). A very rare BRAF 3-base-pair in-
sertion at codon 599, resulting in duplication of threonine
599 (T599dup), was detected in a multifocal, stage III PTC
that developed distant metastases within 4.5 years
(Figure 2B). Both, T599del and T599dup were confined to
the tumor.lesions
Family history BRAF status1
neg pos wt mut
5 2 10 0
19 5 46 0
8 0 18 0
11 2 68 1 T599del
2 2 16 1 K601E
27 4 43 1 T599insT, 70 V600E, 1 K601E
9 4 35 6 V600E, 1 K601E
10 4 46 10 V600E
1 1 7 1 V600E
Table 2 Distribution of tumor stages and BRAF mutations
in thyroid malignancies
Stage PTC FVPTC micro PTC FTC non-WDTC
I 74 [31/43] 24 [19/5] 53 [45/9] 11 [10/1] 0
II 9 [4/5] 6 [4/2] 0 2 1 [0/1]
III 15 [3/12] 7 2 [1/1] 3 0
IV 15 [5/10] 4 1 1 7
Unknown 2 [0/2] 1
BRAFwt/BRAFmut cases in brackets.
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and distant metastasis (P = 0.001) were significantly more
common in PTC patients aged 45 years and older (Table 3).
Patients with BRAFwt PTC were on average younger thanFigure 1 Hematoxylin and eosin stains of thyroid cancer cases harbo
magnification 40 x; right column, original magnification 400 x. A and B, FTC
focus, marked by arrows. C and D, PTC with BRAF K601E mutation. The rec
Conventional PTC and squamous components are intermixed. E and F, FA
solitary encapsulated nodule and misses nuclear features of PTC.those with BRAFmut PTC (36.6 years vs. 43.8 years; P = 0.025).
LN involvement in PTC associated with tumor size (P = 0.044),
and vessel invasion (P = 0.013). Tumor size was slightly, but
not significantly, larger in BRAFmut than in BRAFwt PTC
(3.6 cm vs. 2.9 cm; determined for 87 cases). Considering all
histological types of TC as a group, i.e. PTC, FVPTC, micro
PTC, FTC, and non-WDTC, family history of thyroid disease
positively correlated with capsular invasion (P = 0.025).
Discussion
This study is one of the first comprehensive surveys on
BRAF mutations in different types of thyroid diseases car-
ried out so far in the MENA region. In general, frequency,
distribution, and risk assessment of BRAF mutations in TC
differ between studies emphasizing that the genetic etiologyring new or rare BRAF mutations. Left column, original
with a BRAF K601E mutation. Case has a single minimally invasive
urrence of the case involves subcutaneous tissue and skeletal muscle.
harboring a deletion of BRAF codon 599. The tumor presents as a
Figure 2 New and sporadic BRAF mutations in thyroid neoplasms. A, a new 3-base-pair deletion at codon 599 identified in a FA resulting in
deletion of threonine 599 (p.T599del). B, a rare 3-base pair insertion at codon 599 found in an aggressive PTC resulting in duplication of
threonine 599 (p.T599dup). Deleted and inserted nucleotides and codons are underlined.
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ied [15,16]. The overall incidence of BRAF mutations iden-
tified in our series and the gradation of frequency of BRAF
mutations between PTC and FVPTC are similar to those
displayed in other studies [17]. The detection rate ofTable 3 Significant associations of demographic/
clinocopathological data and BRAF mutations in thyroid
malignancies
Factors1 Histology P value Test2
Age ≥ 45 years vs. tumor size ≥ 4 cm [87] PTC 0.018 FET
Age ≥ 45 years vs. vessel invasion [113] PTC 0.004 FET
Age ≥ 45 years vs. distant metastasis [115] PTC 0.001 FET
LN + vs. tumor size ≥ 4 cm [43] PTC 0.044 FET
LN + vs. vessel invasion [59] PTC 0.013 FET
Increasing age vs. BRAFmut [115] PTC 0.025 MWU
Family history vs. capsular invasion [64] TC 0.025 FET
1Number of cases included in analysis in brackets; 2FET, Fisher`s exact test;
MWU, Mann–Whitney U test.BRAFmut in PTC varies between approximately 30% and
85% while for FVPTC the rate varies between 0% and 35%
with on average ~15% measured across different studies
[7,17-20]. Only a few studies have revealed a similar large
discrepancy in age distribution between BRAFwt and
BRAFmut tumors as we did [21-23] whereas other investiga-
tors did not reveal any significant difference and a metana-
lysis on the clinicopathological impact of BRAF mutations
in PTC could not compile age specific differences across six
evaluated studies [17,24]. The overall young age distribu-
tion in our series can be attributed to the young population
structure of the region.
In general, significance of the BRAF mutational status in
regard to clinicopathological features and clinical treatment
of the disease is still matter of debate although a trend of
BRAF mutation with aggressive tumor markers like vessel in-
vasion, capsular invasion, tumor extension, or LN metastases
has been revealed in a number of studies [10,16,17,24,25].
We attribute the low clinicopathological significance of
BRAF mutations in our series to the fact that this driver
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The specific correlation of BRAF mutations with poor out-
come seems to become more evident in long-term follow-up
studies [23,26]. In contrast, BRAF mutations in micro PTC
are less likely to correlate with clinicopathological factors
[27]. These data coincide with our findings. Our observation
that capsular invasion correlates with family history of TC
warrants further exploration to sustain these findings and to
identify possible genetic predisposition effects in affected
individuals.
The K601E mutation, identified in our series in one case
each of FTC, FVFTC, and PTC is known to be associated
with FVPTC histology [9,24,28-30]. BRAF mutations in TC
others than the V600E mutation are commonly associated
with non-aggressive tumors [31]; however, association of
T599dup and K601E mutations with advanced TC has been
reported [32,33].
BRAF mutations in FA have only been identified so far
sporadically and are almost K601E mutations which FA have
in common with their follicular malignant counterparts
[30,34,35]. The novel T599del mutation detected in a FA in
our series affects one of the two critical phosphorylation sites
(T599 and S602) in the activation domain encoded by exon
15. Phosphorylation of these residues disrupts the hydropho-
bic association of the phosphate-binding loop (P loop) with
the activation loop (A loop) [8,36]. It can be hypothesized
that deletion of codon 599 confers a conformational change
in a similar manner as phosphorylation of T599 which
results in destabilization of the inactive conformation and
switch into the active configuration. Further studies have to
reveal if the T599del is functionally linked to FA develop-
ment which would separate it from other BRAF mutations
evolving in TC.
The T599dup identified in an aggressive PTC in our series
has been recently uncovered as an activation mutation in
pilocytic astrocytomas and a small number of ATC with tall
cell features [33,37,38]. The T599dup exhibited an elevated
kinase activity in transfection assays similarly to V600E [38].
The authors supposed that addition of an extra amino acid
residue at this position rather than addition of a second
threonine phosphorylation site results in disruption of the
inhibitory conformation of the activation loop. Of notice, a
considerable number of sporadic mutations in BRAF exon
15 affects or co-affects codon 599 in TC [24,39-43]. These
mutations tested so far exhibit elevated kinase activity em-
phasizing the critical cofunction of codon 599 in the BRAF
activation process [8,38,40,42].
Conclusions
Significant findings of our study include new and rare
BRAF mutations in malignant and non-malignant thyroid
tumors that in cases of T599dup and K601E seem to confer
a certain risk for progressive TC. Other notable findings in-
clude correlation of capsular invasion with family history ofTC whereas BRAF mutational status disclosed only limited
associations with clinicopathological factors in our series.
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